Evidence map›Paper›PMID 36445542›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2023

Metformin treatment and acute ischemic stroke outcomes in patients with type 2 diabetes: a retrospective cohort study.

Yating Jian, Heying Wang, Lili Zhao, Tao Li, Lei Zhang, Xiaoya Wang, Yiheng Zhang, Ye Li, Meijuan Dang, Ziwei Lu and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Yating JianDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China.
Heying WangDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China.
Lili ZhaoDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China.
Tao LiDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China.
Lei ZhangDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China.
Xiaoya WangDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China.ORCID http://orcid.org/0000-0003-1297-1528
Yiheng ZhangDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China.
Ye LiDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China.
Meijuan DangDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China.
Ziwei LuDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China.
Jialiang LuDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China.
Yuxuan FengDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China.
Yang YangDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China.
Guilian ZhangDepartment of Neurology, the Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwulu Xi'an, Shaanxi, 710004, China. zhgl_2006@126.com.ORCID http://orcid.org/0000-0002-9682-093X
Second Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

National Natural Science Foundation of China 81971116Shanxi Provincial Key Research and Development Project 2019ZDLSF01-04
6 · The paper itself

Abstract

background and purposePreclinical studies have shown that metformin has neuroprotective actions in stroke. However, the optimal treatment timing and duration remain unknown. Herein, we examined the efficacy of metformin treatment on prognosis in acute ischemic stroke (AIS) patients, and assessed the optimal treatment timing and duration.

methodsAIS patients with type 2 diabetes mellitus were retrospectively enrolled. Patients were grouped into those who never received metformin (MET - group), those who received metformin continuously before stroke and after admission (pre-stroke + /post-stroke + group), those who only received metformin before stroke onset (pre-stroke + /post-stroke - group), and those who only received metformin after admission (pre-stroke - /post-stroke + group). The all MET + group represents the sum of the three metformin treatment groups. The efficacy outcome was the 90-day modified Rankin Scale (mRS) score.

resultsIn total, 309 eligible patients were included (MET - [N = 130], pre-stroke + /post-stroke + [N = 94], pre-stroke + /post-stroke - [N = 30], pre-stroke - /post-stroke + [N = 55]; all MET + [N = 179]). The all MET + group had a trend toward a lower 90-day mRS score compared with that in the MET - group (1 [0-2] vs 1 [0-3], unadjusted odds ratio [OR] = 0.652, P = 0.041; adjusted OR = 0.752, P = 0.218). In the three metformin treatment groups, only the pre-stroke + /post-stroke + group had a significantly lower 90-day mRS score (1 [0-1] vs 1 [0-3], adjusted OR = 0.497, 95%CI = 0.289-0.854; P = 0.011) and higher proportion of mRS score 0-1 (78.7% vs. 61.5%, adjusted OR = 2.278, 95%CI = 1.108-4.680; P = 0.025) than the MET - group.

conclusionAIS patients with type 2 diabetes mellitus who receive continuous metformin treatment before stroke onset and after admission have improved functional outcome at 90 days.

Indexed as

Brain IschemiaDiabetes Mellitus, Type 2Ischemic StrokeMetforminStrokeHumansRetrospective StudiesTreatment OutcomeMetforminAcute ischemic strokeDiabetes mellitusMetforminPrognosis

Identifiers

PMID36445542
OpenAlexW4310463331

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.